# Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

> **NCT04874948** · PHASE1 · COMPLETED · sponsor: **Michael Hoelscher** · enrollment: 4 (actual)

## Conditions studied

- Tuberculosis
- Tuberculosis, Pulmonary
- Bacterial Infections Respiratory
- Lung Diseases
- Mycobacterium Infections

## Interventions

- **DRUG:** 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043

## Key facts

- **NCT ID:** NCT04874948
- **Lead sponsor:** Michael Hoelscher
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-08
- **Primary completion:** 2021-10-15
- **Final completion:** 2021-11-09
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04874948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04874948, "Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04874948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*